2D Speckle-tracking Echocardiography in Chemotherapy-induced Cardiomyopathy With Cardiovascular Risk Factors

NCT ID: NCT04547465

Last Updated: 2023-08-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-09-15

Study Completion Date

2023-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aims of this study is to evaluate the role of 2D speckle-tracking echocardiography in diagnosis chemotherapy related left ventricular dysfunction in breast cancer patients with cardiovascular risks

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Chemotherapy induced cardiomyopathy is a serious adverse effect of anticancer treatments with poor long-term prognosis. In addition to the cumulative dose of anthracycline and trastuzumab, cardiovascular risks have been proven to be the "second hit" when dealing with chemotherapy related cardiomyopathy in breast cancer patients. Speckle-tracking echocardiography have had robust evidence in diagnosis the early stage of left ventricular dysfunction in various types of cancer treated by cardiotoxicity drugs. However, data is still lacking regarding the role of speckle-tracking echocardiography in breast cancer patients with cardiovascular risk

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiomyopathy Due to Drug Breast Cancer Cardiovascular Risk Factor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Echocardiography

2D Speckle-tracking echocardiography

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Breast cancer patients treated by anthracycline and/or trastuzumab
* Have at least one of these cardiovascular risks: age \> 60, hypertension, atrial fibrillation, diabetes mellitus, dyslipidemia, chronic kidney disease, obesity, family history of cardiovascular diseases.

Exclusion Criteria

* Left ventricular ejection fraction \< 50% before chemotherapy
* Chronic heart failure with NYHA functional class \>= II
* Significant valvular stenosis/regurgitation
* Acute heart failure due to acute coronary syndrome during follow-up
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Gia Dinh People Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hai H. Nguyen, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Cardiology Department

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nguyen Hoang Hai

Ho Chi Minh City, , Vietnam

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Vietnam

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Nhat M. Giang, M.D

Role: CONTACT

+84919963999

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Nguyen H. Hai, Ph.D

Role: primary

+84-908247359

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

230/HĐĐĐ-ĐHYD

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.